Windtree announces trial design of Phase 2b study of Istaroxime published

Windtree Therapeutics announced the trial design of its SEISMiC Phase 2b has been published by the European Society of Cardiology Heart Failure. The article is entitled, “Safety and efficacy of up to 60 hours of intravenous istaroxime in pre-cardiogenic shock patients: Design of the SEISMiC trial.” “This article reviews and explains key aspects of the Phase 2b trial including design, assessments and procedures, outcome measures and its endpoints,” said Dr. Steve Simonson, Chief Medical Officer and Senior Vice President at Windtree. “This clinical study approach has been the foundation for the istaroxime studies in early cardiogenic shock as well as the ongoing SEISMiC C study that is testing istaroxime in more severe SCAI Stage C cardiogenic shock patients. We are pleased with how the program is progressing toward Phase 3 readiness in cardiogenic shock.”